{
    "clinical_study": {
        "@rank": "142982", 
        "arm_group": [
            {
                "arm_group_label": "gemcitabine and abraxane", 
                "arm_group_type": "Experimental", 
                "description": "Gemcitabine and Abraxane will be administered on an outpatient basis on Days 3, 10, 17, 31, 38, and 45 as an intravenous infusion.  The dose on Day 3 will be 1000 mg/m of gemcitabine followed by a 125 mg/m2 of abraxane and the infusion will take 1 hour.  The second dose and infusion time may be decreased.  Prior to each gemcitabine infusion, subjects will be pre-medicated with an FDA-approved anti-emetic (anti-nausea medication) in an effort to prevent nausea, at the discretion of the study physician."
            }, 
            {
                "arm_group_label": "gemcitabine, abraxane and hydroxychloroquine", 
                "arm_group_type": "Experimental", 
                "description": "Gemcitabine and Abraxane will be administered on an outpatient basis on Days 3, 10, 17, 31, 38, and 45 as an intravenous infusion.  The dose on Day 3 will be 1000 mg/m of gemcitabine followed by a 125 mg/m2 of abraxane and the infusion will take 1 hour.  The second dose and infusion time may be decreased.  Prior to each gemcitabine infusion, subjects will be pre-medicated with an FDA-approved anti-emetic (anti-nausea medication) in an effort to prevent nausea, at the discretion of the study physician.\nHydroxychloroquine is an oral drug (capsule) that subjects will take once or twice a day at home. The dose of hydroxychlorquien will be 1200mg. This is an experimental drug.  Subjects will take their first dose of hydroxychloroquine on Day 1 (48 hours before the first infusion of gemcitabine/abraxane), and will continue to take it every day until the day before surgery."
            }
        ], 
        "brief_summary": {
            "textblock": "This is a randomized phase II trial that will examine the ability of the hydroxychloroquine\n      to improve the clinical activity of a pre-operative regimen of gemcitabine and\n      nab-paclitaxel in subjects with potentially resectable adenocarcinoma of the pancreas.\n      Eligible subjects will receive 2 cycles of gemcitabine and nab-paclitaxel (day 1, 8, 15)\n      with or without hydrocychloroquine  followed by surgical resection.  Primary endpoint will\n      be histologic response as graded by Evans criteria.  Secondary endpoints will be CA19-9\n      response and PET response. Pre and post treatment tissue biopsies will be obtained to assess\n      for levels of autophagy in tumor, liver and peripheral blood."
        }, 
        "brief_title": "Randomized Phase II Trial of Pre-Operative Gemcitabine and Nab Paclitacel With or With Out Hydroxychloroquine", 
        "completion_date": {
            "#text": "November 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Pancreatic Cancer", 
        "condition_browse": {
            "mesh_term": "Pancreatic Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subjects with biopsy-proven potentially resectable or borderline adenocarcinoma of\n             the pancreas as determined by National Comprehensive Cancer Network (NCCN) criteria\n\n          -  Karnofsky performance status of 70-100%\n\n          -  No active second malignancy except for basal cell carcinoma of the skin\n\n          -  Patient has adequate biological parameters as demonstrated by the following blood\n             counts at screening\n\n          -  Absolute neutrophil count (ANC) \u22651.5 \u00d7 109/L;\n\n          -  Platelet count \u2265100,000/mm3 (100 \u00d7 109/L);\n\n          -  Hemoglobin (Hgb) \u22659 g/dL.\n\n          -  Patient has the following blood chemistry levels at Baseline\n\n          -  aspartate aminotransferase (AST) (SGOT), Alanine transaminase (SGPT) \u22642.5 \u00d7 upper\n             limit of normal range (ULN)\n\n          -  Total bilirubin \u2264ULN\n\n          -  Serum Creatinine \u2264 1.5mg/dl OR calculated creatinine clearance \u2265 50 for those\n             patients with creatinine greater than 1.5\n\n          -  Prothrombin time (PT)within normal limits (WNL). If patient is on warfarin for\n             prophylactic clot presentation for indwelling catheter, Partial PT/PTT may be +/- 15\n             %\n\n          -  thromboplastin time (PTT) WNL. If patient on warfarin for prophylactic clot\n             presentation for indwelling catheter, PT/PTT may be +/- 15 %\n\n          -  Age >18 years.\n\n          -  Patient must be able to swallow enteral medications with no requirement for a feeding\n             tube. Patient's must not have intractable nausea or vomiting which prohibits the\n             patient from oral medications\n\n          -  Ability to understand and the willingness to sign a written informed consent\n             document.\n\n        Exclusion Criteria:\n\n          -  Subjects deemed surgically unresectable or subjects unwilling to undergo surgical\n             resection.\n\n          -  Subjects who have received chemotherapy within 12 months prior to randomization.\n\n          -  Prior use of radiotherapy or investigational agents for pancreatic cancer.\n\n          -  Any evidence of metastasis to distant organs (liver, lung, peritoneum).\n\n          -  Symptomatic evidence of gastric outlet obstruction\n\n          -  Inability to adhere to study and/or follow-up procedures\n\n          -  History of allergic reactions or hypersensitivity to the study drugs\n             (hydroxychloroquine, gemcitabine, abraxane).\n\n          -  Women of child-bearing potential and men must agree to use adequate contraception\n             (hormonal or barrier method of birth control; abstinence) prior to study entry and\n             for the duration of study participation. All females of childbearing potential must\n             have a blood test or urine study within two weeks prior to randomization to rule out\n             pregnancy.\n\n          -  Patients with porphyria are ineligible.\n\n          -  Patients with psoriasis are ineligible unless the disease is well controlled and they\n             are under the care of a specialist who agrees to monitor the patient for\n             exacerbations.\n\n          -  Patients requiring the use of enzyme-inducing anti-epileptic medication that\n             includes: phenytoin, carbamazepine, phenobarbital, primidone or oxcarbazepine are\n             excluded.\n\n          -  Patients with previously documented macular degeneration or diabetic retinopathy are\n             excluded.\n\n          -  Baseline electrocardiogram (EKG) with corrected QT interval (QTc) >470 msec\n             (including subjects on medication). Subjects with ventricular pacemaker for whom QT\n             interval is not measurable will be eligible on a case-by-case basis.\n\n          -  Patient with a history of interstitial lung disease, history of slowly progressive\n             dyspnea, sarcoidosis, silicosis, idiopathic pulmonary fibrosis or pulmonary\n             hypersensitivity pneumonitis\n\n          -  Patient with known active infection with HIV, Hepatitis B or Hepatitis C\n\n          -  Patients requiring use of warfarin for therapeutic purposes."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 30, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01978184", 
            "org_study_id": "UPCI# 13-074"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "gemcitabine and abraxane", 
                    "gemcitabine, abraxane and hydroxychloroquine"
                ], 
                "intervention_name": "gemcitabine", 
                "intervention_type": "Drug", 
                "other_name": "Gemzar"
            }, 
            {
                "arm_group_label": [
                    "gemcitabine and abraxane", 
                    "gemcitabine, abraxane and hydroxychloroquine"
                ], 
                "intervention_name": "abraxane", 
                "intervention_type": "Drug", 
                "other_name": "nab-Paclitacel"
            }, 
            {
                "arm_group_label": "gemcitabine, abraxane and hydroxychloroquine", 
                "intervention_name": "hydroxychloroquine", 
                "intervention_type": "Drug", 
                "other_name": "Plaquenil"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Hydroxychloroquine", 
                "Gemcitabine", 
                "Paclitaxel"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "Pancreatic Cancer, resectable adenocarcinoma of the pancreas", 
        "lastchanged_date": "November 6, 2013", 
        "location": {
            "contact": {
                "email": "zehxhx@UPMC.EDU", 
                "last_name": "Herbert Zeh, MD", 
                "phone": "412-692-2852"
            }, 
            "facility": {
                "address": {
                    "city": "Pittsburgh", 
                    "country": "United States", 
                    "state": "Pennsylvania", 
                    "zip": "15232"
                }, 
                "name": "Hillman Cancer Center"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Randomized Phase II Trial of Pre-Operative Gemcitabine and Nab Paclitacel With or With Out Hydroxychloroquine", 
        "overall_official": {
            "affiliation": "University of Pittsburgh CancerCenters", 
            "last_name": "Herbert Zeh, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "November 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Histologic response to pre-operative gemcitabine/ nab-paclitaxel", 
            "safety_issue": "No", 
            "time_frame": "up to 3 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01978184"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Pittsburgh", 
            "investigator_full_name": "Herbert J. Zeh, III MD, FACS", 
            "investigator_title": "Chief of the Division of Gastrointestinal (GI) Surgical Oncology", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Carbohydrate antigen 19-9 (CA19-9) response to pre-operative gemcitabine/ nab-paclitaxel", 
                "safety_issue": "No", 
                "time_frame": "Up to 3 years"
            }, 
            {
                "measure": "Rate of R0 resection and positive lymph node ratio", 
                "safety_issue": "No", 
                "time_frame": "Up to 3 years"
            }
        ], 
        "source": "University of Pittsburgh", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Pittsburgh", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}